Adele Gulfo

Adele Gulfo is Chief Commercial and Business Development Officer at Sumitovant. Gulfo is a member of the Board of Directors of Myovant Sciences, a majority-owned company of Sumitovant Biopharma, and served as the company’s interim CCO from May 2020 to May 2021. Before joining Sumitovant, Gulfo served as Chief of Commercial Development at Roivant Sciences. Previously Gulfo served as President and General Manager of Pfizer’s $12B+ US primary care business unit, comprised of over 5,000 employees across multiple therapeutic areas. She also ran Pfizer’s Commercial Operations, and as US Country Chair led the Managed Care organization across all biopharmaceutical businesses, including Specialty, Oncology, and Vaccines. She ran the Latin America biopharmaceutical business for Pfizer including primary care, oncology, rare disease and vaccines across 23 countries. During this time, revenue grew while reducing expenses. Gulfo has over 25 years of experience in the bio pharmaceutical industry and also held executive level roles at Mylan and AstraZeneca. She has experience launching and growing many well-known blockbuster brands including Crestor, Lipitor, Viagra, Celebrex, Lyrica, Premarin and Eliquis. Gulfo also serves on the boards of Medexus Pharma and Enpro Industries. She received a BS in Biology and Chemistry and MBA in Marketing from Seton Hall University. Gulfo also received an MBA with a Pharma emphasis from Fairleigh Dickinson University and trained in Post Grad Molecular Biology at the University of Medicine and Dentistry of New Jersey.